Please login to the form below

Not currently logged in
Email:
Password:

Metrics appoints director of pharma development

Promotion for Joseph Cobb at contract development and manufacturing organisation

Joseph Cobb has been named as the director of pharmaceutical development at the US contract development and manufacturing company Metrics.

The appointment is a promotion for Cobb, who has been with North Carolina-based Metrics since 2002, serving most recently as associate director of pharmaceutical development.

In his new role, Cobb will oversee Metrics' work in early-phase solid oral dosage development, as well as the company's potent and cytotoxic drug development services.

These services cover pharmaceutical formulation development; first-time- in-man formulations; and the manufacturing of clinical materials for trials covering phase I to III.

“Joe is a smart and capable leader who has been instrumental in guiding the success and growth of Metrics' formulation development capabilities,” said Phil Hodges, president of the company, which operates as a subsidiary of Mayne Pharma.

“With these new responsibilities, Joe will bring to his role the same thoughtfulness and resourcefulness.”

7th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....